Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148
This study is recruiting at 8 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced HR+/HER2- Breast Cancer
- Advanced CCNE1-amplified Solid Tumors
- Extensive-stage Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- August 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California LA · Los Angeles, CA
Florida · 1
- Florida Cancer Specialists · Fort Myers, FL
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Missouri · 1
- WA Uni School Of Med · St Louis, MO
New York · 1
- Memorial Sloan Kettering · New York, NY
Tennessee · 1
- SCRI Oncology Partners · Nashville, TN
Texas · 1
- MD Anderson Cancer Center Uni of Te · Houston, TX
Washington · 1
- Fred Hutch Cancer Research · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.